US lawmakers introduced the Enhancing CLIA Act of 2026 to update oversight of laboratory-developed tests (LDTs) after a 2025 court decision said LDTs are medical services and not FDA-regulated devices. The bill would require CMS to create an LDT database, enable voluntary third-party review, and establish centralized error reporting—seeking clearer validation standards without duplicative FDA-type requirements.